Why the study?
Heterogeneity in clinician interpretation of troponin profiles limits rapid triage protocols, and prospective validation of machine learning models for risk assessment and phenotyping myocardial injury is needed.
Does an AI-based clinical decision-support tool reduce cardiovascular mortality, MI, and unplanned readmissions in patients presenting to the ED with suspected cardiac symptoms?
Does an AI-based clinical decision-support tool reduce cardiovascular mortality, MI, and unplanned readmissions in patients presenting to the ED with suspected cardiac symptoms?
This study design outlines a cluster-randomized trial to evaluate whether an AI-based clinical decision support tool can improve clinical outcomes for patients presenting with suspected cardiac chest pain.
ML models may reduce troponin-interpretation heterogeneity in ED chest pain; leaves open outcome impact and should not yet change practice.
BACKGROUND: Clinical work-up for suspected cardiac chest pain is resource intensive. Despite expectations, high-sensitivity cardiac troponin assays have not made decision making easier. The impact of recently validated rapid triage protocols including the 0-hour/1-hour hs-cTn protocols on care and outcomes may be limited by the heterogeneity in interpretation of troponin profiles by clinicians. We have developed machine learning (ML) models which digitally phenotype myocardial injury and infarction with a high predictive performance and provide accurate risk assessment among patients presenting to EDs with suspected cardiac symptoms. The use of these models may support clinical decision-making and allow the synthesis of an evidence base particularly in non-T1MI patients however prospective validation is required. OBJECTIVE: We propose that integrating validated real-time artificial intelligence (AI) methods into clinical care may better support clinical decision-making and establish the foundation for a self-learning health system. DESIGN: This prospective, multicenter, open-label, cluster-randomized clinical trial within blinded endpoint adjudication across 12 hospitals (n = 20,000) will randomize sites to the clinical decision-support tool or continue current standard of care. The clinical decision support tool will utilize ML models to provide objective patient-specific diagnostic probabilities (ie, likelihood for Type 1 myocardial infarction [MI] versus Type 2 MI/Acute Myocardial Injury versus Chronic Myocardial Injury etc.) and prognostic assessments. The primary outcome is the composite of cardiovascular mortality, new or recurrent MI and unplanned hospital re-admission at 12 months post index presentation. SUMMARY: Supporting clinicians with a decision support tool that utilizes AI has the potential to provide better diagnostic and prognostic assessment thereby improving clinical efficiency and establish a self-learning health system continually improving risk assessment, quality and safety. TRIAL REGISTRATION: ANZCTR, Registration Number: ACTRN12620001319965, https://www.anzctr.org.au/.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: